UK-RNQD-220099. DOP: June 2022.
Hear from dermatology experts across the UK
on the following topics:
 - Andrew Pink.png)
Where are we now in atopic dermatitis (AD)?
Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust
RINVOQ mode of action in AD
Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust
Clinical overview of RINVOQ: MEASURE UP 1 and 2
Dr Hamish Hunter, Consultant Dermatologist at Salford Royal NHS Foundation Trust
.png)
HEADS UP trial overview
Dr Ben Walker, Consultant Dermatologist at Harrogate and District NHS Foundation Trust
RINVOQ for treating AD in adolescents
Dr Jen Sharif, Consultant Dermatologist, Salford Royal NHS Foundation Trust
.png)
AD UP: clinical efficacy and safety of RINVOQ + TCS
Dr Ben Walker, Consultant Dermatologist at Harrogate and District NHS Foundation Trust
Initiating Therapy
Dr Eirini Merika, Consultant Dermatologist at Chelsea and Westminster Hospital, London
The Impact of AD: Patient Stories
Teena Mackenzie, Biologic, Inflammatory Disease and Research CNS at Royal Berkshire Hospital and Oxford University Hospitals NHS Trust
1. RINVOQ Summary of Product Characteristics
UK-RNQD-220108. Date of preparation: May 2022
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
